Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Abstract

Metabolic (dysfunction) associated steatotic liver disease (MASLD) formerly known as non‐alcoholic fatty liver disease (NAFLD) is a growing global health concern with no approved pharmacological treatments. At the same time, there are no standard methods to definitively screen for the presence of MASLD because of its progressive nature and symptomatic commonality with other disorders. Recent advances in molecular understanding of MASLD pathophysiology have intensified research on development of new drug molecules, repurposing of existing drugs approved for other indications, and an educated use of dietary supplements for its treatment and prophylaxis. This review focused on depicting the latest advancements in MASLD research related to small molecule development for prophylaxis or treatment and diagnosis, with emphasis on mechanistic basis at the molecular level.This article is protected by copyright. All rights reserved.